The medicine is generally used to complement diet and other supportive measures. Its therapeutic use is applied across domains where additional symptomatic support is needed. These include conditions characterized by periods of heightened symptoms, such as primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.

---

Managing Elevated Triglycerides and Cholesterol

This medication is commonly used across conditions presenting with acute episodes, assisting with managing symptoms related to systemic imbalance when symptoms become more noticeable.

“This medication supports the patient during difficult episodes by easing distress.”

Quick Support: Addresses Systemic Imbalance

---

Supportive Relief in Clinical Contexts

The medication is relevant in contexts marked by increased discomfort or tension, particularly in conditions where functional stability becomes affected. It is applicable within clinical settings that involve acute or disruptive symptom patterns, and may assist with easing the overall symptom burden. It contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with symptom fluctuations.

The eligibility for Lipidil 145 One (fenofibrate) is strictly defined by regulatory documents, focusing on patient population and pre-existing conditions. The medicine is authorized for adult patients (18 years and older) who meet specific criteria for dyslipidemia.

Absolute Contraindications

The medication must not be used in populations with absolute exclusions listed in the regulatory label:

• Severe Renal Impairment (eGFR < 30 mL/min/1.73 m^2).
• Active Liver Disease, including primary biliary cirrhosis.
• Pre-existing Gallbladder Disease.
• Known Hypersensitivity to fenofibrate, related fibrates, or excipients like peanut oil or soya lecithin.
• Pregnancy or Lactation.

Population Restrictions

Use is not recommended for children and adolescents under 18 years because safety and efficacy have not been established by regulators.

Patients with mild to moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m^2) are eligible for use, but their dose is required to be reduced. Eligibility for older adults is dependent upon the status of their renal function. The medicine is also contraindicated if a patient is simultaneously taking another medication from the fibrate class.

Interactions with other medicines and products

Lipidil 145 One’s interaction profile is documented based on pharmacokinetic and pharmacodynamic patterns, establishing regulatory requirements for co-administered substances.

---

High-Risk and Pharmacodynamic Interactions

Co-administration with HMG-CoA reductase inhibitors (Statins) is associated with an increased risk of serious muscle toxicity (myopathy and rhabdomyolysis). This pharmacodynamic risk is officially noted as heightened in specific populations, including elderly patients and those with diabetes, renal failure, or hypothyroidism.

---

Pharmacokinetic and Exposure Constraints

Fenofibrate officially potentiates the effect of Coumarin anticoagulants (e.g., Warfarin), a finding linked to the mild-to-moderate CYP2C9 inhibitory capacity of the active metabolite, fenofibric acid. This potentiation requires a corresponding dosage reduction of the anticoagulant to maintain the desired International Normalized Ratio (INR). Furthermore, the combined use of Fenofibrate with the immunosuppressant Cyclosporine has been officially associated with reports of severe, reversible renal function impairment.

---

Administration-Timing and Restriction Rules

To ensure proper absorption, a mandatory time separation rule applies: Lipidil 145 One must be taken at least one hour before or four to six hours after bile acid sequestrants (resins). Use is strictly contraindicated in patients with severe renal impairment, as regulatory data confirms that fenofibric acid clearance decreases substantially in this condition, leading to systemic drug accumulation.

The mechanism of action for Lipidil 145 One, driven by Fenofibrate, is centered on the selective activation of the nuclear receptor Peroxisome Proliferator-Activated Receptor alpha (PPARα), primarily in the liver. This agonism initiates a fundamental genetic cascade that alters the body's fat and lipoprotein metabolism.

Activation of PPARα alters gene transcription, resulting in the upregulation of the enzyme Lipoprotein Lipase (LPL) and the downregulation of its natural inhibitor, Apolipoprotein C-III (ApoC-III). The resulting combined action accelerates the breakdown and removal of triglyceride-rich particles, such as VLDL, directly from the bloodstream, leading to a reduction in plasma triglyceride levels.

Simultaneously, the mechanism modulates the structure of cholesterol carriers. It enhances the synthesis of key Apolipoproteins (ApoA-I, ApoA-II), which are essential components of HDL cholesterol. This action influences the reverse cholesterol transport pathway and induces a shift in the quality of circulating LDL particles, favoring larger, less dense phenotypes.

Official Administration Guidelines

Lipidil 145 One (fenofibrate 145 mg) is administered according to established instructions to ensure proper usage. The medication is delivered exclusively via the oral route as a fixed-dose capsule or tablet. Its specific formulation, often involving micronized particles, allows for flexible scheduling, meaning it may be taken as a single dose at any time of day and with or without food.

---

Standard Dosage and Use Protocol

Instruction	Detail
Route of administration	Oral (swallowing)
Dosing schedule	145 mg orally once daily (standard and maximum dose)
Administration Timing	Any time of day; with or without food
Preparation requirements	Must be swallowed whole; do not crush, chew, or break

The standard regimen for primary hyperlipidaemia and mixed dyslipidaemia is the 145 mg dose taken once daily. Treatment is not structured as a short course but as an ongoing plan that requires periodic reassessment. Dosage adjustments are determined following repeat lipid determinations, typically evaluated at four to eight week intervals. If an adequate response is not achieved after two to three months of treatment at the maximum recommended dose, discontinuation of the therapy is considered.

Special Procedural Constraints

Specific constraints apply to the administration of this treatment. If a patient is also taking a bile acid binding resin (a different type of medication), the fenofibrate dose must be spaced at least one hour before or four to six hours after the resin to prevent absorption interference. Should a dose be missed, the instruction is to skip the missed dose and continue with the next scheduled dose; do not take an extra or double dose to compensate.

For geriatric patients or those with mild-to-moderate renal impairment, dose selection must be guided by an evaluation of renal function, potentially necessitating a starting dose lower than 145 mg.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Studies investigated whether Lipidil 145 One (fenofibrate) was associated with changes in lipid profiles in patients with mixed dyslipidemia or severe hypertriglyceridemia. Research protocols specified that patients enrolled in these trials met specific criteria for lipid levels and disease severity. The primary endpoint of the initial randomized, controlled trial was the change in specific validated lipid parameters at 12 weeks.

Study 1: Short-term outcomes

The first major trial examined patients over a 12-week period. Research examined the drug's effect profile.

• Findings reported a specific mean change in triglyceride and cholesterol levels, compared to the placebo group.
• The trial recorded the frequency of reported adverse events, such as headache, nausea, and injection site reactions.

Study 2: Long-term exposure

Studies evaluated the use of the drug over a period of at least 6 months. This trial included an open-label extension phase, which provided long-term follow-up data on a subset of the original population. Trial data reported on adverse event rates associated with long-term use of the drug. The Study 2 protocol observed changes in outcomes following a dose adjustment.

Research into Combination Approaches

Research compared the outcomes of fenofibrate therapy combined with statins against statin monotherapy in a population subset that had not reached target lipid levels with standard initial treatment. Trials explored the association between the approach and changes in cardiovascular risk markers.

• This research assessed outcomes using various clinical, laboratory, and patient-reported measures.

Context and Future Research

Overall, research has explored the drug's activity in various disease contexts. Further studies are ongoing to continue to investigate the drug's activity across the spectrum of lipid disorders.

Common questions about Lipidil 145 One (FAQ)

Q: How long does it usually take to see results from Lipidil 145 One in blood tests?

Studies indicate that changes in blood lipid levels are often assessed between 6 to 12 weeks after starting treatment. To determine if the medicine is achieving its intended effect, a healthcare professional typically performs initial checks of lipid levels within 4 to 8 weeks.

---

Q: Is Lipidil 145 One a long-term treatment, or is it used for a short time?

According to official product information, Lipidil 145 One is generally intended for ongoing, long-term treatment to help manage blood fat levels. Regulatory documents describe the treatment as an ongoing process requiring periodic reassessment by a healthcare professional.

---

Q: Are there common side effects that usually go away after a few weeks of taking Lipidil 145 One?

Some commonly reported side effects, such as mild stomach problems and temporary changes in liver enzyme readings, are often described as transient. This means they occur more frequently when first starting the treatment and may resolve over time.

---

Q: Is Lipidil 145 One generally considered appropriate for people over 70 years old?

Official guidance requires that the evaluation of kidney function be a guiding factor for dose selection in older adults. This is important because reduced kidney function may lead to the medicine accumulating in the body.

---

Q: How is the efficacy of Lipidil 145 One monitored by a healthcare professional?

Efficacy is primarily monitored through periodic blood tests that measure the patient's lipid profile, including triglyceride and cholesterol levels. These tests are typically done at intervals of four to eight weeks after starting the medicine.

---

Q: Why is continuous treatment with Lipidil 145 One required, and why should it not be stopped suddenly?

The medicine works to regulate fat levels but does not cure the underlying condition, so continuous therapy is required. Regulatory information indicates that abrupt discontinuation may lead to a rapid return of elevated triglyceride and cholesterol levels.

---

Q: Does Lipidil 145 One interact with other cholesterol-lowering medicines like ezetimibe?

Official information notes that combining fibrates, like Lipidil 145 One, with certain other cholesterol-lowering agents, such as ezetimibe, has been linked to an increased risk of gallstones and potential muscle issues. Official prescribing information states that any combination therapy necessitates careful monitoring by a healthcare professional.

---

Q: How is Lipidil 145 One different from other lipid-lowering drugs?

Lipidil 145 One belongs to the fibrate class of medicines. Fibrates are differentiated by their primary action of activating the PPARalpha receptor (a specific nuclear receptor) to boost the breakdown and clearance of triglycerides from the bloodstream.

---

Q: Does Lipidil 145 One help raise 'good cholesterol' (HDL)?

Studies and official information indicate that fenofibrate is generally associated with an increase in HDL cholesterol levels, especially in patients who start with lower baseline levels. The drug’s mechanism enhances the synthesis of key components that make up the HDL particle.

---

Q: Can taking Lipidil 145 One affect blood cell counts?

Official labeling mentions that mild to moderate decreases in certain blood measures, including hemoglobin, hematocrit, and white blood cell counts, have been observed. These levels usually stabilize with continued administration.

---

Q: Are there specific food allergies, like peanut or soy, that prevent someone from using Lipidil 145 One?

Yes, regulatory documents list a contraindication (a reason not to use the medicine) for patients with a known hypersensitivity to the active ingredient or its inactive components. These components may include ingredients derived from peanut oil or soya lecithin.

---

Q: Is there a known interaction between Lipidil 145 One and alcohol consumption?

Although there is no direct chemical interaction, official guidance notes that heavy alcohol consumption may increase blood fat levels (counteracting the medicine’s effect) and can heighten the risk of side effects like liver damage and pancreatitis.

---

Q: What are the signs of a serious skin reaction related to Lipidil 145 One?

Serious skin reactions are rare but possible. Signs that may suggest a serious skin reaction include a painful rash, blisters on the skin or mucous membranes (like the mouth), or swelling of the face or throat. These reactions require prompt medical evaluation.

---

Q: Can Lipidil 145 One cause joint pain or back pain?

Official adverse event reports indicate that both back pain and joint pain have been reported as possible side effects. Any occurrence of unusual muscle pain, weakness, or tenderness is a sign that requires review by a healthcare provider.

---

Q: What are the potential signs of pancreas inflammation (pancreatitis) while taking this medicine?

Pancreatitis is listed as an uncommon adverse reaction. Potential signs include severe abdominal pain that may spread to the back, often accompanied by nausea, vomiting, or fever.

---

Q: Does Lipidil 145 One cause increased sensitivity to sunlight (photosensitivity)?

Yes, photosensitivity (increased skin sensitivity to sunlight) is a reported side effect of fenofibrate. The medicine is contraindicated in anyone who has a prior history of skin reactions to fibrate medicines caused by sun exposure.

---

Q: How does Lipidil 145 One differ from a lower dosage of fenofibrate?

Lipidil 145 One (145 mg) is the standard adult dose for most uses. Lower dosages of fenofibrate are generally reserved for patients with special circumstances, such as those with mild-to-moderate reduced kidney function, as specified in regulatory documents.

---

Q: Is the risk of side effects higher when Lipidil 145 One is taken with a statin?

Official drug interaction warnings confirm that co-administration with statins is associated with an increased risk of serious muscle toxicity, including myopathy and rhabdomyolysis. This risk is noted as heightened in certain patient populations.

---

Q: Does Lipidil 145 One affect fertility or sexual function?

Erectile dysfunction is reported as an uncommon side effect in regulatory documents. Furthermore, animal studies have indicated that fenofibrate has been associated with effects on male reproductive organs.

---

Q: Is Lipidil 145 One safe for use during pregnancy?

The use of Lipidil 145 One is contraindicated (must not be used) during pregnancy or breast-feeding. This restriction is based on insufficient data regarding the risk to human pregnancy and the potential for the medicine to pass to the infant.

---

Q: Can Lipidil 145 One cause gout or an increase in uric acid levels?

Clinical trial evidence suggests that fenofibrate often leads to a reduction in uric acid levels and has been associated with a lower incidence of gout in certain study populations.

---

Q: What should a patient do if they experience flu-like symptoms while taking this medication?

Since muscle aches and fever can be symptoms of flu or, in rare cases, signs of serious muscle toxicity (myopathy), the occurrence of unexplained muscle pain, tenderness, or weakness requires review by a healthcare provider.

---

Q: What does the term 'fibrates' mean in relation to this medicine?

A fibrate is the pharmacological class of medicine to which fenofibrate belongs. Fibrates are a specialized type of agent that manages high levels of fats in the blood by activating the PPARalpha receptor to boost the clearance of fat particles.

---

Q: Can Lipidil 145 One be taken by patients who have had gallbladder removal surgery?

Fenofibrate is contraindicated in patients with pre-existing gallbladder disease. Eligibility for use after gallbladder removal surgery requires a healthcare professional's evaluation.

---

Q: Does Lipidil 145 One affect appetite or cause weight changes?

Clinical reports have listed both weight gain and weight loss as side effects of unknown incidence. Additionally, loss of appetite is noted as a potential symptom that can be related to other adverse events like liver problems.

How to Store and Dispose of Lipidil 145 One

Lipidil 145 One (Fenofibrate) must be stored under specific environmental controls to maintain product stability, as defined in regulatory labeling.

---

Storage Requirements

Detail	Requirement
Temperature	Store at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F).
Protection	Protect from moisture and light. Do not freeze the medicine.
Container	Must be kept in the original container or blister pack.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Lipidil 145 One should be returned to a pharmacist for proper disposal. If a take-back program is unavailable, follow the official guidance to safely dispose of the medicine by mixing it with an undesirable substance (e.g., kitty litter) and placing it in a sealed bag before disposal in household trash. Do not flush the medicine down the sink or toilet.